GRIMALDI, Elena
 Distribuzione geografica
Continente #
EU - Europa 209
NA - Nord America 133
AS - Asia 76
SA - Sud America 4
AF - Africa 2
Totale 424
Nazione #
US - Stati Uniti d'America 131
IT - Italia 90
IE - Irlanda 74
HK - Hong Kong 32
SG - Singapore 31
DE - Germania 17
GB - Regno Unito 10
CN - Cina 8
BR - Brasile 4
AT - Austria 3
NL - Olanda 3
GR - Grecia 2
KR - Corea 2
SE - Svezia 2
BE - Belgio 1
BG - Bulgaria 1
CA - Canada 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ES - Italia 1
FR - Francia 1
LT - Lituania 1
MD - Moldavia 1
MY - Malesia 1
PK - Pakistan 1
SC - Seychelles 1
TR - Turchia 1
UA - Ucraina 1
Totale 424
Città #
Dublin 74
Naples 40
Santa Clara 37
Hong Kong 32
Singapore 17
Chandler 15
Aversa 10
New York 8
Bremen 7
Princeton 7
Roxbury 7
Pescara 6
Cambridge 4
Caserta 4
Jacksonville 4
Napoli 4
Amsterdam 3
Bacoli 3
Los Angeles 3
Medford 3
Munich 3
Rome 3
Boardman 2
Falkenstein 2
Nuremberg 2
Redwood City 2
Santa Croce sull'Arno 2
Seoul 2
Vienna 2
Algiers 1
Bauru 1
Beijing 1
Boston 1
Boydton 1
Brussels 1
Chicago 1
Des Moines 1
Drochia 1
Frankfurt am Main 1
Goiânia 1
Istanbul 1
Kamoke 1
Manassas 1
Miami 1
Monteforte Irpino 1
Nanjing 1
Ottawa 1
Parla 1
Prague 1
Praia A Mare 1
Rawang 1
Rio de Janeiro 1
Sala Consilina 1
Salerno 1
San Leucio 1
Shanghai 1
Sofia 1
Turin 1
Woodbridge 1
Águas de Lindóia 1
Totale 339
Nome #
Tuberculosis infection screening in 5468 italian healthcare students: Investigation of a borderline zone value for the QFT-test 70
Seven years prevalence and distribution of high and low risk HPV genotypes in women living in the metropolitan area of Naples 53
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod 52
Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab 50
Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab 50
Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab 47
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod 38
Distribution of Hepatitis C Virus Genotypes and Subtypes in the Metropolitan Area of Naples, Italy, in the Era of Interferon-Free Regimens. 36
Efficacy and safety of tixagevimab-cilgavimab (Evusheld®) in people with Multiple Sclerosis on Ocrelizumab: preliminary evidence 29
Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy 22
Totale 447
Categoria #
all - tutte 2.774
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.774


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 4 0
2020/202112 0 1 3 0 2 1 3 0 0 0 2 0
2021/202244 0 0 2 3 12 0 0 0 4 3 4 16
2022/2023131 12 1 3 5 13 9 0 8 69 1 5 5
2023/202464 3 1 5 2 16 8 0 6 7 3 5 8
2024/2025175 3 2 9 2 50 34 16 20 28 11 0 0
Totale 447